COMMUNIQUÉS West-GlobeNewswire

HNL Lab Medicine Expands Services with New Pocono Creek Patient Service Center Featuring Dedicated Pediatric Phlebotomy Space
21/01/2026
BARTONSVILLE, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a trusted leader in comprehensive laboratory testing services, is pleased to announce the opening of its newest Patient Service Center in [...]
FSR Announces $400,000 Investment in New Round of Cardiac and Pilot Grant Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
21/01/2026
CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at Chicago, Dr. Chieh [...]
Alignment Healthcare Named to the 2026 Fortune World’s Most Admired Companies™ List for First Time
21/01/2026
In its first year of eligibility, award-winning Medicare Advantage company earns spot on global corporate reputation list, joining major corporations like Amazon and Apple ORANGE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE [...]
CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP
21/01/2026
CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy , global logistics partnerships , and sustainability roadmap supporting the commercial [...]
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
21/01/2026
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company [...]
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
21/01/2026
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, [...]
PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device
21/01/2026
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical [...]
American Heart Association and Centre for Neuro Skills Deepen Relationship to Advance Stroke and Brain Injury Care
21/01/2026
Multi-year Sponsorship Expands Across Texas and California with Educational Resources, Community Leadership and Patient Support BAKERSFIELD, Calif. and AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Centre for Neuro [...]
Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region
21/01/2026
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore Brain Logo ST. LOUIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Restore [...]
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
21/01/2026
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY [...]
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC
21/01/2026
TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and [...]
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
21/01/2026
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
“Medical Travel Month” January 2026 Sponsored by Medical Travel & Digital Health News in SHSMD American Hospital Association’s Calendar of Health Observances
21/01/2026
OAKLAND, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Medical Travel & Digital Health News (MTDHN) , the leading bi-monthly online newsletter covering the business of medical travel and digital solutions worldwide, today [...]
Manhattan Wellness Joins Lumina Therapy Alliance, Expanding the Nation’s Premier In-Person Mental Health Network
21/01/2026
Led by visionary founder Jennifer Teplin, Manhattan Wellness strengthens Lumina’s footprint for New York’s business community and signals rapid national expansion. NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lumina [...]
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
21/01/2026
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in vision in 2024 KNOXVILLE, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
21/01/2026
New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
21/01/2026
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare Marketing CAMPBELL, Calif. and NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD). For nearly three decades, [...]
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
21/01/2026
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional [...]
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
21/01/2026
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000 [...]

Pages